Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:CSBR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.88-2.8%$0.76$0.46▼$1.32$9.66M0.316,075 shs11,652 shsCSBRChampions Oncology$6.23-0.3%$6.03$5.50▼$9.63$86.54M0.417,818 shs3,815 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+4.11%+11.26%+32.33%+1.12%-26.23%CSBRChampions Oncology-1.11%-1.42%+3.99%+6.47%-24.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.88-2.8%$0.76$0.46▼$1.32$9.66M0.316,075 shs11,652 shsCSBRChampions Oncology$6.23-0.3%$6.03$5.50▼$9.63$86.54M0.417,818 shs3,815 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+4.11%+11.26%+32.33%+1.12%-26.23%CSBRChampions Oncology-1.11%-1.42%+3.99%+6.47%-24.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/ACSBRChampions Oncology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BCLI and CSBR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ACSBRChampions Oncology$56.94M1.54$0.46 per share13.78$0.27 per share23.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$1.64N/AN/AN/AN/AN/A-519.50%8/17/2026 (Estimated)CSBRChampions Oncology$4.70M-$0.16N/AN/AN/A-3.94%-57.31%-7.51%7/16/2026 (Estimated)Latest BCLI and CSBR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/16/2026Q4 2026CSBRChampions Oncology-$0.05N/AN/AN/A$12.89 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21CSBRChampions OncologyN/A0.980.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CSBRChampions Oncology41.30%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%CSBRChampions Oncology46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableCSBRChampions Oncology14313.89 million7.44 millionOptionableBCLI and CSBR HeadlinesRecent News About These CompaniesChampions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 | finanznachrichten.deChampions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 | accessnewswire.comAChampions Oncology, Inc.: Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMarch 31, 2026 | finanznachrichten.deChampions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMarch 30, 2026 | accessnewswire.comAChampions Oncology, Inc. (NASDAQ:CSBR) Q3 2026 Earnings Call TranscriptMarch 14, 2026 | insidermonkey.comChampions Oncology, Inc. (CSBR) Q3 2026 Earnings Call TranscriptMarch 12, 2026 | seekingalpha.comChampions Oncology Reports Revenue of $16.6 MillionMarch 12, 2026 | accessnewswire.comAChampions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026March 5, 2026 | accessnewswire.comAIs Champions Oncology, Inc.'s (NASDAQ:CSBR) Latest Stock Performance A Reflection Of Its Financial Health?January 17, 2026 | uk.finance.yahoo.comChampions Oncology (CSBR) Earnings Call TranscriptJanuary 7, 2026 | fool.comChampions Oncology (CSBR) Earnings TranscriptJanuary 7, 2026 | finance.yahoo.comWhy Champions Oncology, Inc.’s (CSBR) Stock Is Down 5.41%December 16, 2025 | aaii.comAChampions Oncology signals expanding radiolabeling and data platform as margin improves to 52%December 16, 2025 | msn.comChampions Oncology, Inc. (NASDAQ:CSBR) Q2 2026 Earnings Call TranscriptDecember 16, 2025 | insidermonkey.comChampions Oncology, Inc. (CSBR) Q2 2026 Earnings Call TranscriptDecember 15, 2025 | seekingalpha.comChampions Oncology Reports Record Quarterly Service Revenue of $14.9 MillionDecember 15, 2025 | accessnewswire.comAChampions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025December 8, 2025 | accessnewswire.comAChampion of Champions snooker 2025 order of play today – Monday 10th NovemberNovember 10, 2025 | radiotimes.comRChampion of Champions snooker 2025 LIVE RESULTS: Judd Trump WINS, Lei thrashes Murphy, Wilson waits – updatesNovember 10, 2025 | thesun.co.ukTrump through to Champion of Champions quartersNovember 10, 2025 | msn.comMedia Sentiment Over TimeBCLI and CSBR Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$0.88 -0.03 (-2.78%) As of 03:07 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Champions Oncology NASDAQ:CSBR$6.23 -0.02 (-0.32%) As of 02:50 PM EasternChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips BitMine’s Ethereum Bet Is Only Part of the Story SpaceX Valuation Loses Altitude as AI Risks Mount Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
